| Pretreatment CRP/ALB ratio | ||
---|---|---|---|
Low | High | p value | |
Gender | |||
 Male | 36 | 21 |  |
 Female | 27 | 15 | 1.000 |
Age | |||
 <65 | 34 | 19 |  |
 ≥65 | 29 | 17 | 1.000 |
Location of primary tumor | |||
 Colon | 36 | 21 |  |
 Rectum | 27 | 15 | 1.000 |
Detection of unresectable tumor | |||
 Synchronous | 34 | 25 |  |
 Metachronous | 29 | 11 | 0.143 |
Histological type | |||
 Well, moderately | 51 | 27 |  |
 Poorly, mucinous | 9 | 3 | 0.744 |
Peritoneal dissemination | |||
 Negative | 47 | 33 |  |
 Positive | 16 | 3 | 0.061 |
The number of organs affected by metastasis | |||
 One organ | 36 | 18 |  |
 Multiple organs | 27 | 18 | 0.534 |
Pretreatment CEA (ng/ml) | |||
 ≤5 | 9 | 4 |  |
 >5 | 53 | 31 | 0.765 |
Molecular targeted therapy | |||
 No | 17 | 12 |  |
 Yes | 46 | 24 | 0.503 |
Pretreatment mGPS | |||
 0 | 63 | 6 |  |
 1 | 0 | 21 |  |
 2 | 0 | 9 | <0.001 |
Pretreatment NLR | |||
 <3 | 41 | 13 |  |
 ≥3 | 18 | 22 | 0.003 |